1️⃣ Lilly just paid for the next gene-editing bet
Lilly and Profluent said on April 28 that they signed a multi-program genetic-medicines deal worth up to $2.25B in milestones plus royalties, giving Lilly exclusive rights to AI-designed recombinases for larger DNA insertions.
Why it matters
Money is moving past base editing toward gene insertion. That widens the disease map and raises the bar for editing platforms built for narrower fixes.
Coffee talk
Gene-editing money just moved to gene insertion. Which platforms are still selling yesterday’s bottleneck?
2️⃣ EMA just opened a pilot lane for breakthrough devices
EMA launched its breakthrough medical devices pilot on April 28, offering free expert-panel support and priority advice for class III and certain class IIb active devices, with phase Ia applications due by May 22.
Why it matters
Europe finally has a structured early lane for high-risk devices. That changes evidence planning, timing and where MedTech teams lean in.
Coffee talk
If EMA is opening an early lane for high-risk devices, is Europe still the slow lane or just the late-planning lane?
3️⃣ Biotech IPOs are testing the public window again
Seaport and Hemab updated IPO filings on April 27, both marketing shares at $16 to $18 and each targeting roughly $180M in net proceeds at the midpoint, adding two more biotech names to this week’s Nasdaq queue.
Why it matters
The signal is not another funding deck. It is two clinical-stage companies asking public investors to price risk again.
Coffee talk
Two biotechs are back in the IPO queue in the same week. How many crossover funds actually want the work?